Rapid, Cost-Effective Peptide/Nucleic Acid-Based Platform for Therapeutic Antibody Monitoring in Clinical Samples.

Marco Mocenigo, Alessandro Porchetta, Marianna Rossetti, Erik Brass, Lucia Tonini, Luca Puzzi, Elda Tagliabue, Tiziana Triulzi, Bruna Marini, Francesco Ricci, Rudy Ippodrino

Research output: Contribution to journalArticlepeer-review

Abstract

We demonstrate here a homogeneous assay, named NanoHybrid, for monoclonal antibody quantification directly in serum samples in a single-step format. NanoHybrid is composed of both synthetic peptide nucleic acids (PNAs) and nucleic acid strands conjugated to recognition elements and optical labels and is designed to allow fast fluorescence quantification of a therapeutic antibody. More specifically, we have characterized our analytical assay for the detection of trastuzumab (Herceptin), a monoclonal antibody (mAb) drug used for breast cancer treatment and for tumors overexpressing the HER2/neu protein. We show here that NanoHybrid is capable of performing fast drug quantification directly in blood serum. The results obtained with a pool of samples from breast cancer patients under trastuzumab treatment are compared with CE-IVD ELISA (enzyme-linked immunosorbent assay) showing a good agreement (Cohen's K = 0.729). Due to the modular nature of the NanoHybrid platform, this technology can be programmed to potentially detect and quantify any antibody for which a high-affinity recognition element has been characterized. We envision the application of NanoHybrid in a point-of-care (POC) drug monitoring system based on disposable kits for therapeutic drug management.
Original languageEnglish
Pages (from-to)3109-3115
Number of pages7
JournalACS Sensors
Volume5
Issue number10
DOIs
Publication statusPublished - Oct 1 2020

Keywords

  • *immunotherapy
  • *DNA nanoswitches
  • *optical biosensor
  • *serological test
  • *trastuzumab

Fingerprint Dive into the research topics of 'Rapid, Cost-Effective Peptide/Nucleic Acid-Based Platform for Therapeutic Antibody Monitoring in Clinical Samples.'. Together they form a unique fingerprint.

Cite this